ATE519838T1 - Verfahren zur herstellung von rohbakterienstämmen und deren verwendung - Google Patents

Verfahren zur herstellung von rohbakterienstämmen und deren verwendung

Info

Publication number
ATE519838T1
ATE519838T1 AT06820577T AT06820577T ATE519838T1 AT E519838 T1 ATE519838 T1 AT E519838T1 AT 06820577 T AT06820577 T AT 06820577T AT 06820577 T AT06820577 T AT 06820577T AT E519838 T1 ATE519838 T1 AT E519838T1
Authority
AT
Austria
Prior art keywords
bacteria strains
producing raw
raw bacteria
producing
strains
Prior art date
Application number
AT06820577T
Other languages
English (en)
Inventor
John Stanford
Cynthia Stanford
Graham Mcintyre
Oscar Bottasso
Original Assignee
Bioeos Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioeos Ltd filed Critical Bioeos Ltd
Application granted granted Critical
Publication of ATE519838T1 publication Critical patent/ATE519838T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/32—Mycobacterium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
AT06820577T 2005-12-21 2006-12-19 Verfahren zur herstellung von rohbakterienstämmen und deren verwendung ATE519838T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0526033.6A GB0526033D0 (en) 2005-12-21 2005-12-21 Method
PCT/GB2006/004780 WO2007071978A1 (en) 2005-12-21 2006-12-19 Method of producing rough strains of bacteria and uses thereof

Publications (1)

Publication Number Publication Date
ATE519838T1 true ATE519838T1 (de) 2011-08-15

Family

ID=35840894

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06820577T ATE519838T1 (de) 2005-12-21 2006-12-19 Verfahren zur herstellung von rohbakterienstämmen und deren verwendung

Country Status (15)

Country Link
US (2) US8071354B2 (de)
EP (2) EP2298860A3 (de)
JP (1) JP5202330B2 (de)
CN (1) CN101384699B (de)
AT (1) ATE519838T1 (de)
AU (1) AU2006328209B2 (de)
BR (1) BRPI0620291B8 (de)
CA (1) CA2633127C (de)
DK (1) DK1963484T3 (de)
ES (1) ES2369569T3 (de)
GB (1) GB0526033D0 (de)
NZ (1) NZ568810A (de)
PL (1) PL1963484T3 (de)
SI (1) SI1963484T1 (de)
WO (1) WO2007071978A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0716778D0 (en) * 2007-08-29 2007-10-10 Bioeos Ltd Use
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201216800D0 (en) * 2012-09-20 2012-11-07 Immodulon Therapeutics Ltd Novel use
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
WO2016207646A1 (en) 2015-06-24 2016-12-29 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
US20200061130A1 (en) * 2016-02-25 2020-02-27 Thomas Julius Borody Compositions and methods of treatment of chronic infectious diseases
KR20190020805A (ko) * 2016-06-24 2019-03-04 앱티뮨 바이올로직스, 인코포레이티드 수스의 면역 시스템을 프라이밍하는 방법
TWI767013B (zh) 2017-06-14 2022-06-11 英商4D製藥研究有限公司 包含細菌品系之組成物
US11077179B2 (en) 2017-08-10 2021-08-03 Epicgenetics, Inc. Method for treating fibromyalgia and chronic fatigue syndrome
TW202034949A (zh) * 2018-11-02 2020-10-01 英商4D製藥研究有限公司 包含細菌菌株之組成物
WO2020115161A1 (en) 2018-12-04 2020-06-11 Sabiotec Spin-Off Sl Immunostimulant for use against pathogens
AU2019396657A1 (en) 2018-12-12 2021-07-08 4D Pharma Research Limited Compositions comprising Parabacteroides bacterial strains for treating cancer
JP7712684B2 (ja) * 2020-01-21 2025-07-24 ▲遼▼▲寧▼格瑞仕特生物制▲藥▼有限公司 ロドコッカス・ルーバーの細胞壁骨格の再生医学における用途
GB202004007D0 (en) * 2020-03-19 2020-05-06 Immodulon Therapeutics Ltd Coronavirus

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1054055A (en) 1975-05-27 1979-05-08 Institut Armand-Frappier Isolation and characterization of phenotypes of mycobacteria
EP0487633A4 (en) 1989-08-17 1993-10-20 Surgical Laser Products, Inc. Integral end structure for medical laser waveguide
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
WO1992008488A1 (en) 1990-11-08 1992-05-29 University College London Mycobacterium as adjuvant for antigens
AU9027191A (en) 1990-11-05 1992-05-26 Bsd Medical Corporation Urethral inserted applicator for prostate hyperthermia
US5521300A (en) 1991-08-13 1996-05-28 Norval B. Galloway Oligonucleotides complementary to mycobacterial nucleic acids
ES2158854T3 (es) 1992-10-13 2001-09-16 Hoffmann La Roche Oligonucleotidos derivados de la familia de genes sod.
US6136529A (en) 1993-09-03 2000-10-24 Gen-Probe Incorporated Nucleic acid probes to Mycobacterium avium complex
US5721209A (en) 1995-02-03 1998-02-24 The Regents Of The University Of California Iron chelator and inhibitor of iron-mediated oxidant injury
US5994346A (en) 1995-02-03 1999-11-30 Regents Of The University Of California Use of exochelins in the preservation of organs for transplant
US5786326A (en) 1995-02-03 1998-07-28 Horwitz; Lawrence D. Method for the treatment of atherosclerosis and vascular injury by prevention of vascular smooth muscle cell proliferation
JP4241929B2 (ja) 1996-05-22 2009-03-18 ジェン―プローブ・インコーポレーテッド Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｋａｎｓａｓｉｉを検出するための組成物および方法
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
GB9701897D0 (en) 1997-01-30 1997-03-19 Aqua Health Europ Ltd Vaccine
US7067500B2 (en) 1997-05-02 2006-06-27 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US7329410B1 (en) * 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
DE19911208A1 (de) 1999-03-13 2000-09-14 Walther Carl Kurt Gmbh Steckkupplung zur Verbindung von Rohrleitungen, Schläuchen oder dergleichen
GB0025694D0 (en) 2000-10-19 2000-12-06 Univ London Vaccine
US6900204B2 (en) 2001-09-06 2005-05-31 Activbiotics, Inc. Antimicrobial agents and uses thereof
US7122525B2 (en) 2001-11-21 2006-10-17 Activbiotics, Inc. Targeted therapeutics and uses thereof
US7078399B2 (en) 2001-12-13 2006-07-18 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
US20040014750A1 (en) 2001-12-13 2004-01-22 Michaelis Arthur F. Metal complexes and formulations of rifamycin analogues and uses thereof
WO2003068918A2 (en) 2002-02-11 2003-08-21 Auburn University High-sensitivity real-time polymerase chain reaction for detection of nucleic acids
AU2003239919A1 (en) 2002-06-03 2003-12-19 Activbiotics, Inc. Intravenous rifalazil formulation and methods of use thereof
AR041171A1 (es) 2002-09-06 2005-05-04 Univ London Modulador inmune
EP1684803B1 (de) 2003-11-14 2010-07-07 UCL Business PLC Immunmodulator mit ganzzell-tsukamurella bakterien
US7442374B2 (en) 2004-07-19 2008-10-28 Ucl Biomedica Plc Composition for increasing the survival to slaughter rate of piglets
KR20070089250A (ko) * 2004-12-27 2007-08-30 페더럴-모걸 파워트레인, 인코포레이티드 엔진 마운트용 열 차폐장치

Also Published As

Publication number Publication date
US8071354B2 (en) 2011-12-06
ES2369569T3 (es) 2011-12-02
EP1963484A1 (de) 2008-09-03
US20120082699A1 (en) 2012-04-05
CA2633127A1 (en) 2007-06-28
US8512694B2 (en) 2013-08-20
CN101384699A (zh) 2009-03-11
SI1963484T1 (sl) 2012-06-29
JP2009520489A (ja) 2009-05-28
NZ568810A (en) 2011-09-30
AU2006328209A1 (en) 2007-06-28
DK1963484T3 (da) 2011-09-19
WO2007071978A1 (en) 2007-06-28
ES2369569T8 (es) 2012-06-26
PL1963484T3 (pl) 2012-08-31
EP2298860A2 (de) 2011-03-23
US20090304749A1 (en) 2009-12-10
CN101384699B (zh) 2012-10-10
AU2006328209B2 (en) 2012-10-11
JP5202330B2 (ja) 2013-06-05
GB0526033D0 (en) 2006-02-01
BRPI0620291A2 (pt) 2011-11-08
BRPI0620291B8 (pt) 2021-05-25
EP2298860A3 (de) 2012-04-25
CA2633127C (en) 2015-08-04
BRPI0620291B1 (pt) 2020-12-15
EP1963484B1 (de) 2011-08-10

Similar Documents

Publication Publication Date Title
EP2085419A4 (de) Verfahren zur herstellung von modifiziertem polymer, nach dem verfahren erhaltenes modifiziertes polymer und kautschukzusammensetzung damit
WO2009158658A3 (en) Induction of flocculation in photosynthetic organisms
WO2007134294A3 (en) Novel chlorella species and uses therefor
EP3795716C0 (de) Verfahren und produktionsanlage zur herstellung von hochfestem kaltgewalztem stahlblech mit ausgezeichneter chemischer konvertierbarkeit
ATE534620T1 (de) Verfahren zur herstellung von isocyanaten
SI1963484T1 (sl) Postopek za proizvodnjo surovih sevov bakterije in uporaba le-teh
ATE514738T1 (de) Partikuläre wachskomposite und verfahren zu deren herstellung sowie deren verwendung
EP2350013A4 (de) Zusammensetzungen zur markierung und identifizierung von autophagosomen sowie verfahren zu ihrer herstellung und verwendung
DE502006005290D1 (de) Niedrigviskose uretdiongruppenhaltige polyadditionsverbindungen, verfahren zur herstellung und verwendung
ATE547531T1 (de) Verfahren zur herstellung von l-methionin unter verwendung coryneformer bakterien
ATE516290T1 (de) Verfahren zur herstellung von buprenorphin und derivaten von buprenorphin
EP1718732A4 (de) Verfahren zur herstellung und verwendung von der haut abgeleiteter stammzellen
ATE367167T1 (de) Aufbereitung von aldesleukin zur pharmazeutischen verwendung
ATE480248T1 (de) Verwendung von milchsäurebakterien zur verringerung von zahnfleischbluten und mundentzündung
ATE434940T1 (de) Verfahren zur verbesserung der immunfunktion bei säugern unter verwendung von lactobacillus reuteri-stämmen
EP4656754A4 (de) Stahlblech und element sowie verfahren zur herstellung des stahlblechs und verfahren zur herstellung des besagten elements
ATE458743T1 (de) Zwischenprodukt und verfahren zur herstellung von an beta-anomeren angereicherten 2'-desoxy,2',2'- difluor-d-ribufuranosylnukleosiden
EP4110793A4 (de) Genetisch manipulierte mikroorganismen, die mikrocin-mge überexprimieren, und verfahren zur reinigung und verwendung
ATE488508T1 (de) Verfahren zur herstellung von irbesartan und zwischenprodukte davon
ATE335855T1 (de) Bakterien und verfahren zur herstellung von riboflavin durch fermentation
MY140061A (en) Improved method for the production of ramipril
EP4656755A4 (de) Stahlblech und element sowie verfahren zur herstellung des stahlblechs und verfahren zur herstellung des besagten elements
EP1896581A4 (de) Substanzen, zusammensetzungen und verfahren zur vorbeugung und behandlung immunvermittelter entzündungskrankheiten
DE602005016377D1 (de) Geformter holzartikel und verfahren zur herstellung des geformten holzartikels
EP4380529A4 (de) Rollstuhllift und verfahren zur herstellung und verwendung davon

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1963484

Country of ref document: EP